Latest News - Novartis

Monday, November 13, 2017 | Clinical Trials, Retina, Novartis

Novartis: Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity in nAMD

Novartis announced further positive results from two phase 3 studies of brolucizumab versus aflibercept (Eylea). Results showed noninferiority in primary endpoint, superiority in key retinal health ou…

Read the full story

Tuesday, November 07, 2017 | Conferences, Retina, Novartis

Novartis Pivotal Brolucizumab (RTH258) Data to be Presented at AAO

Novartis will be presenting more detailed results from its phase 3 studies (HAWK and HARRIER) of brolucizumab (RTH258) vs. aflibercept for the treatment of neovascular age-related macular degeneration…

Read the full story

Monday, October 30, 2017 | Acquisitions/Mergers, Novartis

Novartis to buy Advanced Accelerator Applications for $3.9 billion

Novartis announced Monday plans to buy Advanced Accelerator Applications for $3.9 billion in cash, strengthening the company's oncology portfolio. Under the deal, Novartis will gain Advanced Accel…

Read the full story

Monday, September 04, 2017 | Management/Leadership, Alcon, Novartis

Novartis CEO Joseph Jimenez to Retire Next Year; Vasant Narasimhan Named as Replacement

Novartis announced Monday that CEO Joseph Jimenez will step down from his role effective January 31, 2018, to be replaced by Vasant Narasimhan, the company's current global head of drug developmen…

Read the full story

Tuesday, June 20, 2017 | Clinical Trials, AMD, Novartis

Novartis RTH258 (Brolucizumab) Demonstrates Robust Visual Gains in Wet AMD Patients with a Majority on a 12-week Injection Interval

Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two phase 3 studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These …

Read the full story

Wednesday, April 12, 2017 | Partnerships, Novartis

Commentary: Novartis Finds Its Next Mass-Market Ophthalmology Drug Candidate at a Small Virtual Biotech With a Global View

Like me, you may never have heard about Lubris BioPharma before today. But Novartis has. And that is by far more important. Today the pharma giant reached out and exercised an option on a recombinant …

Read the full story

Wednesday, January 25, 2017 | Earnings & Financials, Alcon, Novartis

Novartis Considers Spinning Off Alcon Unit

Novartis said it is considering several options for its Alcon unit, including the possibility of separating from the eye care division. The announcement comes after Novartis reported that Alcon’…

Read the full story

Wednesday, January 18, 2017 | Health Care, Novartis

Novartis CEO: Trump Could Boost Economy but Obamacare Needs to be Replaced if Repealed

Donald Trump's policies could be good for the economy but Obamacare should be replaced if it's repealed, the CEO of drug giant Novartis told CNBC on Tuesday. Joseph Jimenez played down some of…

Read the full story

Tuesday, December 20, 2016 | Acquisitions/Mergers, Novartis

Novartis Bolsters Ophthalmology Pipeline Through Acquisition of Encore Vision

Novartis announced that it has entered into a definitive agreement to acquire Encore Vision, a company focused on the development of a novel treatment in presbyopia. Terms of the deal were not disc…

Read the full story

Monday, November 21, 2016 | Miscellaneous, Alcon, Novartis

Novartis Backs Off From 2016 Date for Testing Google Autofocus Lens

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadil…

Read the full story

Friday, October 14, 2016 | Retina, Novartis

Lucentis Recommended by CHMP for EU Approval in Sixth Indication for the Treatment of Visually Impaired Patients

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal ne…

Read the full story

Thursday, September 01, 2016 | Miscellaneous, Novartis

Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatm…

Read the full story

Friday, June 24, 2016 | Retina, Novartis

CHMP Positive Opinion for Once-Daily Nevanac 3mg/ml (Nepafenac) Eye Drops in Europe

On June 24, 2016, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of once-daily Nevanac 3mg/ml (nepafenac) eye drops, suspension in Europe for the reduction in risk …

Read the full story

Tuesday, April 26, 2016 | Earnings & Financials, Novartis

Novartis May Sell Its $14 Billion Stake in Roche to Fuel Acquisitions

It was built over a decade ago as a basis for a possible merger that never happened. Novartis is discussing options with banks for selling its near $14 billion stake in rival Roche, potentially provid…

Read the full story

Thursday, March 31, 2016 | Earnings & Financials, Novartis

Novartis Publishes Updated 2015 Segment Financials Reflecting New Division Structure

Novartis announced that it has published updated 2015 quarterly and full-year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the…

Read the full story
Load More